In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases

You may be eligible if

• Age18 years
• Affiliated to social security or entitled to
• Patient who has been informed of the study and has signed a free and informed consent
• Patient with GVHD following allogeneic hematopoietic stem cell transplantation (HSC)
• Or with acquired bone marrow suppression
• Lymphocytosis \> 0.5 G/L
• \- Patient with systemic lupus erythematosus (ACR classification criteria)
• \- Patient with multiple sclerosis (criteria of Mc Donald 2017)
• \- Patient with rheumatoid arthritis (ACR classification criteria)
• \- Patient with Basedow disease, Hashimoto's thyroiditis
• \- Patient with vitiligo or alopecia areata or atopic dermatitis
• Patient under guardianship, curatorship or judicial protection
• Pregnant, parturient or breastfeeding woman
• Patient deprived of liberty
• Patient hospitalized without consent
• Patient admitted to a health or social institution for purposes other than research
• Minor patient
• Adult patient unable to express consent
• Refusal to participate
• Patient on AME
• Ongoing treatment with high doses (\>1 mg/kg/d) of systemic corticosteroid therapy
• Ongoing treatment with JAK inhibitors
• Ongoing treatment with doses \>10 mg/d Prednisone
• Ongoing treatment with Cellcept, Endoxan, Imurel, Belimumab, Anti-CD20, Methotrexate
• Ongoing treatment with JAK inhibitors
• Treatment with systemic corticosteroid therapy, Fingolimod or Teriflunomide
• Ongoing treatment with JAK inhibitors
• Lymphocytosis \< 0.5 G/L
• Ongoing treatment with doses \>15 mg/d Prednisone
• Treatment with Rituximab or Tocilizumab
• Ongoing treatment with JAK inhibitors
• Lymphocytosis \< 0.5 G/L
• Ongoing immunosuppressive therapy
• Ongoing treatment with JAK inhibitors
• Ongoing treatment with Methotrexate
• Ongoing treatment with JAK inhibitors
• Ongoing treatment with doses \>10 mg/d prednisone